pace privat label launch broaden moat/pt
 rais pt higher
expect contribut privat label sale
prove accret ep margin time track
show acceler hous brand launch earli
continu believ privat label highli under-appreci
trend one improv user experi grow
retent drive increment revenu ep revis
estim privat label revenu
increment ebitda reinvest
would broaden amazon moat youssef squali
permit grant cogcc well fitzpatrick
merck co inc buy keytruda shine
mrk data show keytruda monotherapi provid
os benefit nsclc trial design drive
success fail data solidifi keytruda
posit squamou nsclc nsclc help
underwhelm data roch see
upward pressur keytruda sale vs street
keytruda lynparza/lenvima combo data bc/rcc
drive allianc revenu contribut om expans
mrk investor meet june local time
discuss data reiter pt ep
buy rate pt believ accret thesi
behind upgrad link remain intact key takeaway
recent travel new presid
month integr mpi remain on-track
excess capac sq ft facil help support
growth least year minim increment capital-expenditure
manufactur appear underappreci despit solid
double-digit growth op margin
expect see uniform industry-wid cyclic freq ask
throughout trip sandi draper
show comer efficaci platinum r/r ovarian
saw encourag efficaci zejula platinum resist
ovarian cancer irrespect subgroup includ group
would expect respond parp alon
hrdneg brcawt patient increment posit
zejula platinum resist ovarian cancer also
 present leav us posit
subgroup bini biliari tract
mct extend holter
oilfield servic equip pressur pump replac
inc new york boston seth
strh reit nareit meet host suntrust
encourag parp io space remind
parp io data reiter buy pt
tiviti follow upbeat analyst day focus strong
core trend coupl multipl lever drive enrol
toward goal ss member ye addit
announc sever new product includ
exercis nutrit rest/recoveri product provid one-
stop shop healthi live final superb trend
robust growth prime ramp new product superb custom
satisfact np capital-expenditure light/strong model
view tiviti well posit reiter buy target
expect analyst day reaffirm structur growth stori expect
analyst day messag reflect modest dramat chang
upcom analyst day expect reiter
margin larg grow expect evolutionari
guidanc opex spend bit captur growth
capit alloc dividend growth opportun
programm analog motion buy remain
among one best idea structur growth semi
retain estim pt base consist blend
p/e/g ev/ebitda/g ev/sales/g william stein
explor product suntrust co governor poll
releas tuesday bmo regulatori concern surround
governor race part reason wattenberg group
trade discount group republican
would ideal market predict dem win
turn dem primari march poli
versu kennedi undecid poli spend
look undecid tell us kennedi chanc regulatori
catalyst histor worth month
wattenberg multipl impact analysi page
oilfield servic equip think pressur
pump oper gener enough ebitda support
build new fleet estim normal ebitda need
mm/year year gener return
cost fleet account mainten spend
capit fluid end pressur pump ebitda need
increas substanti public compani
larg number new fleet order opinion return
normal level gener attract full-
cycl return off-set downturn ken sill
page
electr power util
electr power util power/util macro trend
analysi key macro factor impact power/util
sector includ forward price spark spread dark spread
nation weather pattern base latest peer group
valuat chang price target
permit grant cogcc well fitzpatrick
explor product suntrust co governor poll
releas tuesday bmo regulatori concern surround
governor race part reason wattenberg group
trade discount group republican
would ideal market predict dem win
turn dem primari march poli
versu kennedi undecid poli spend
look undecid tell us kennedi chanc regulatori
catalyst histor worth month
wattenberg multipl impact analysi page
oilfield servic equip think pressur
pump oper gener enough ebitda support
build new fleet estim normal ebitda need
mm/year year gener return
cost fleet account mainten spend
capit fluid end pressur pump ebitda need
increas substanti public compani
larg number new fleet order opinion return
normal level gener attract full-
cycl return off-set downturn ken sill
 explor product pleas see page two
weekli sector comparison compani includ ar
srci vnom neal
program provid strateg advantag pure permian
player given current delawar take-away constraint
midland-l spread forecast crzo soon
temporarili shift capit eagl ford delawar
remaind well ps
multi-basin mani ampl eagl ford inventori
crzo net undril locat estim shift
page
activ vs increas overal activ enabl
compani hit net undril locat estim
shift activ vs increas overal activ enabl
compani hit neal dingmann
investor day preview maintain buy reiter buy
rate pt ahead investor day held
june like major topic includ discuss nashvil
economi futur driver sustain growth hire
integr progress carolina acquisition/
question success plan given
materi manag chang sinc found
believ manag highlight member leadership
team visibl investor jennif demba
solid monthli metric report maintain estim pt
maintain ep estim
follow may monthli metric report continu
post strong account margin loan growth second month
off-set slacken dart forecast continu
expect strong account dart growth
continu post highest account asset growth
industri believ deserv higher multipl
peer despit diminish benefit rate increas
mb inc mbfi hold downgrad
hold buy follow acquisit announc
downgrad mbfi share hold buy due pend
acquisit rate
may announc intent acquir mbfi
acquisit price per share exceed price
target acquisit price confirm thesi mbfi
valuabl profit franchis sharehold align
manag team trade discount increas
pt base announc acquisit term michael
merck co inc buy keytruda shine
mrk data show keytruda monotherapi provid
os benefit nsclc trial design drive
success fail data solidifi keytruda
posit squamou nsclc nsclc help
page
underwhelm data roch see
upward pressur keytruda sale vs street
keytruda lynparza/lenvima combo data bc/rcc
drive allianc revenu contribut om expans
mrk investor meet june local time
discuss data reiter pt ep
buy rate pt believ accret thesi
behind upgrad link remain intact key takeaway
recent travel new presid
month integr mpi remain on-track
excess capac sq ft facil help support
growth least year minim increment capital-expenditure
manufactur appear underappreci despit solid
double-digit growth op margin
expect see uniform industry-wid cyclic freq ask
throughout trip sandi draper
show comer efficaci platinum r/r ovarian
saw encourag efficaci zejula platinum resist
ovarian cancer irrespect subgroup includ group
would expect respond parp alon
hrdneg brcawt patient increment posit
zejula platinum resist ovarian cancer also
encourag parp io space remind
parp io data reiter buy pt
tiviti follow upbeat analyst day focus strong
core trend coupl multipl lever drive enrol
toward goal ss member ye addit
announc sever new product includ
exercis nutrit rest/recoveri product provid one-
stop shop healthi live final superb trend
robust growth prime ramp new product superb custom
satisfact np capital-expenditure light/strong model
view tiviti well posit reiter buy target
olumi restrict maintain pt friday
fda announc approv olumi rheumatoid
arthriti patient inadequ respons one
tnf antagonist label includ black box warn
thrombosi expect requir inadequ
respons increment neg reflect
modestli lower penetr estim maintain buy
rate pt peter lawson
page
year meet celg host analyst event
review discuss sever present includ
transcend r/r aggress nhl
pomalyst phase optimismm r/r mm
updat phase data late line mm data
trial larg posit think stock could volatil
near-term given high expect particularli
come reiter hold rate
 attend mirati provid
increment updat sitravatinib ccrcc present
kinas inhibitor deciphera loxo esai left us
bullish kinas inhibitor space increment
posit kinas name said reiter buy
rate arri peter
data bmi part john bori
 attend saw present
ido inhibitor provid detail recent trial result
saw trio poster cabozantinib liver
cancer show efficaci regardless age prior time
sorafenib also saw encourag initi data array
binimetinib biliari tract cancer reiter buy
arri peter lawson
show encourag subgroup analysi attend
provid increment updat
new gastric cancer total patient margetuximab
keytruda gastric cancer gastroesophag junction
cancer orr mpf slightli
month gi detail subgroup analysi
show encourag result high express
posit patient orr high
increment posit marg gastric cancer reiter buy
pt peter lawson
mesothelioma data receiv like continu combo
attend poster present provid
updat tazemetostat mesothelioma dcr
week tick abstract
also saw orr first time manag
previous note plan advanc taz mesothelioma
like combin reiter buy peter
page
cardio develop all-pay ambulatori ecg unit
model present time good confid regard
medicar unit number trend yet fulli
confirm non-medicar contribut mix variou
monitor categori said medicar unit trend
appear robust key growth segment mct
extend holter bruce nudel
inc buy posit updat data
thyroid bladder cancer watch nektar
show data cabozantinib checkpoint inhibitor bladder
cancer respons rate remain high orr
new cr radioiodin refractori thyroid cancer orr
cabo monotherapi
abstract thyroid repres model
believ data updat increment encourag show
broad applic cabo also saw data nektar
suggest possibl competit io combin
reiter buy rate pt peter lawson
compani buy olumi us
approv label exclus ra-beacon
remain encourag attend adaptimmun
updat ny-eso data encourag one select
oral io present largest confer hall
gain addit patient respons patient
headlin orr dip
confer think ny-eso program look encourag
mrcl given lack therapeut option late line
myxoid patient repres second tumor type gener
respons reiter buy rate pt peter lawson
multipl sclerosi registri support length therapi john
posit data phase ii studi nash
review preclin clinic data
compar
data galm aramchol cymabay seladelpar
believ seladelpar share mani characterist
aramchol differ profil
regard lipid metabol liver enzym compar
galm expect report arrest
page
data june remain cautious optimist outcom
close earn call next day et
estim pt unchang charl bradi
inc buy takeaway
head reitweek prepar upcom
reitweek investor confer nyc surpris
rapid shift sentiment medic offic skill nurs
reit sector ytd mob reit sell-off effect cut
near term invest market disposit
nice off-set primari fund sourc new acquisit
net wash ffo snf reit appear reach
bottom improv reimburs regulatori clariti
sizabl activ draw attent
pace privat label launch broaden moat/pt
 rais pt higher
expect contribut privat label sale
prove accret ep margin time track
show acceler hous brand launch earli
continu believ privat label highli under-appreci
trend one improv user experi grow
retent drive increment revenu ep revis
estim privat label revenu
increment ebitda reinvest
would broaden amazon moat youssef squali
expect analyst day reaffirm structur growth stori expect
analyst day messag reflect modest dramat chang
upcom analyst day expect reiter
margin larg grow expect evolutionari
guidanc opex spend bit captur growth
capit alloc dividend growth opportun
programm analog motion buy remain
among one best idea structur growth semi
retain estim pt base consist blend
p/e/g ev/ebitda/g ev/sales/g william stein
digit entertain market blizzard add
owl team destini major expans reveal come
page
ea broadcast kick ea lgf
kddi deal japan could lift sub famili
aid sub growth help move away in-app bill
googl bring demand audio programmat net posit
 tme valuat per ft would add
valuat gdpr disrupt stabil
relist matthew thornton
ad wix host ad nyc tuesday
expect manag provid updat busi
highlight new features/product traction
far especi code give updat long-term
outlook stock good run ytd vs
iwm compani product focu differenti
freemium offer keep us posit top
questions/top believ top-of-mind investor nave
autom look like key growth driver broader
focus sub-seg import compani
posit factori autom long runway ahead
howev concern stock remain signific
handset exposur inject risk valuat compel
pt stay base ep averag
page
june inc ndr ceo cfo new york boston
june inc group dinner chairmn ceo cfo chairman carolinas/virginia evp carolinas/virginia
june syntel inc synt ndr vice-president financ head ir texa
june corp ndr cfo vice-president treasur ir mid-west kc
june ndr presid ceo cfo kc
june dowdupont inc dwdp ndr director ir financ manag ir director ir kc mid-west
june actuant corp atu ndr ceo ir chicago new
page
june inc ndr cfo vice-president ir mid-west canada
june thor industri inc life fit bc bu tour chicago
june nareit meet host suntrust robinson humphrey new york
june estimate conf call inc new
juli estimate conf call head industri estat new
june jennif demba michael young bank atlanta new
june michael young bank austin new
june jennif demba michael young bank houston dalla new
june mark hugh insur boston new york new
page
june jennif demba michael young bank mid-atlant new
page
issu research report suntrust robinson humphrey inc analyst name report herebi certifi
recommend opinion express accur reflect research analyst person view
subject secur compani discuss herein part research analyst compens directli
indirectli relat specif recommend view express report
